Targeting Nociceptors in Hidradenitis Suppurativa
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Adults between ages 18 and 75 years with established diagnosis of hidradenitis suppurativa (HS)
• HS skin lesions of duration at least 1 year, HS skin lesions in at least two different body areas
Locations
United States
Massachusetts
University of Massachusetts Chan Medical School
RECRUITING
Worcester
Contact Information
Primary
Sarah K Whitley, MD PhD
sarah.whitley@umassmed.edu
(508)856-4086
Backup
Deborah White, Deborah Peduzzi
deborah.white@umassmed.edu
(508)856-2664
Time Frame
Start Date: 2022-06-07
Estimated Completion Date: 2028-04-30
Participants
Target number of participants: 20
Treatments
single group assignment
men or women between the ages of 18-75 who have an established diagnosis of Hidradenitis Suppurativa
Authors
Related Therapeutic Areas
Sponsors
Collaborators: AbbVie, Hidradenitis Suppurativa Foundation, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Leads: University of Massachusetts, Worcester